-
2
-
-
0034688194
-
Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators
-
Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin-converting- enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med. 2000 ; 342: 145-153
-
(2000)
N Engl J Med
, vol.342
, pp. 145-153
-
-
Yusuf, S.1
Sleight, P.2
Pogue, J.3
-
3
-
-
0037160968
-
Cardiovascular morbidity and mortality in the Losartan Intervention for Endpoint reduction in hypertension study (LIFE): A randomised trial against atenolol
-
Dahlöf B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention for Endpoint reduction in hypertension study (LIFE): A randomised trial against atenolol. Lancet. 2002 ; 359: 995-1003
-
(2002)
Lancet
, vol.359
, pp. 995-1003
-
-
Dahlöf, B.1
Devereux, R.B.2
Kjeldsen, S.E.3
-
5
-
-
42649115768
-
Recent advances in the angiotensin-converting enzyme 2-angiotensin(1-7)- Mas axis
-
Santos RAS, Ferreira AJ, Simões E, et al. Recent advances in the angiotensin-converting enzyme 2-angiotensin(1-7)-Mas axis. Exp Physiol. 2008 ; 93: 519-527
-
(2008)
Exp Physiol
, vol.93
, pp. 519-527
-
-
Santos, R.A.S.1
Ferreira, A.J.2
Simões, E.3
-
6
-
-
84865642487
-
Critical evaluation of the efficacy and tolerability of azilsartan
-
De Caterina AR, Harper AR, Cuculi F. Critical evaluation of the efficacy and tolerability of azilsartan. Vasc Health Risk Manag. 2012 ; 8: 299-305
-
(2012)
Vasc Health Risk Manag
, vol.8
, pp. 299-305
-
-
De Caterina, A.R.1
Harper, A.R.2
Cuculi, F.3
-
7
-
-
84868668210
-
TRV120027, a novel β-arrestin biased ligand at the angiotensin II type i receptor, unloads the heart and maintains renal function when added to furosemide in experimental heart failure
-
Boerrigter G, Soergel DG, Violin JD, et al. TRV120027, a novel β-arrestin biased ligand at the angiotensin II type I receptor, unloads the heart and maintains renal function when added to furosemide in experimental heart failure. Circ Heart Fail. 2012 ; 5: 627-634
-
(2012)
Circ Heart Fail
, vol.5
, pp. 627-634
-
-
Boerrigter, G.1
Soergel, D.G.2
Violin, J.D.3
-
8
-
-
84871074661
-
-
Trevena Inc accessed 18 September 2012
-
Trevena Inc, http://www.trevenainc.com (2010, accessed 18 September 2012).
-
(2010)
-
-
-
9
-
-
84870052689
-
Neutral endopeptidase inhibition and the natriuretic peptide system: An evolving strategy in cardiovascular therapeutics
-
Mangiafico S, Costello-Boerrigter LC, Andersen IA, et al. Neutral endopeptidase inhibition and the natriuretic peptide system: An evolving strategy in cardiovascular therapeutics. Eur Heart J. 2012 ;:
-
(2012)
Eur Heart J
-
-
Mangiafico, S.1
Costello-Boerrigter, L.C.2
Andersen, I.A.3
-
10
-
-
84871064839
-
-
Retrophin LLC accessed 18 September 2012
-
Retrophin LLC, http://www.retrophin.com (2011, accessed 18 September 2012).
-
(2011)
-
-
-
11
-
-
65549143348
-
Pharmacodynamic hybrids coupling established cardiovascular mechanisms of action with additional nitric oxide releasing properties
-
Martelli A, Breschi MC, Calderone V. Pharmacodynamic hybrids coupling established cardiovascular mechanisms of action with additional nitric oxide releasing properties. Curr Pharm Des. 2009 ; 15: 614-636
-
(2009)
Curr Pharm des
, vol.15
, pp. 614-636
-
-
Martelli, A.1
Breschi, M.C.2
Calderone, V.3
-
12
-
-
84871047168
-
-
NicOx accessed 18 September 2012
-
NicOx, http://www.nicox.com (2012, accessed 18 September 2012).
-
(2012)
-
-
-
13
-
-
0032973878
-
Angiotensin II type 1 and type 2 receptors bind angiotensin II through different types of epitope recognition
-
Miura S, Karnik SS. Angiotensin II type 1 and type 2 receptors bind angiotensin II through different types of epitope recognition. J Hypertens. 1999 ; 17: 397-404
-
(1999)
J Hypertens
, vol.17
, pp. 397-404
-
-
Miura, S.1
Karnik, S.S.2
-
14
-
-
7444240177
-
Synthesis and AT2 receptor-binding properties of angiotensin II analogues
-
Rosenström U, Sköld C, Lindeberg G, et al. Synthesis and AT2 receptor-binding properties of angiotensin II analogues. J Pept Res. 2004 ; 64: 194-201
-
(2004)
J Pept Res
, vol.64
, pp. 194-201
-
-
Rosenström, U.1
Sköld, C.2
Lindeberg, G.3
-
16
-
-
84871073913
-
-
Lanthio Pharma accessed 18 September 2012
-
Lanthio Pharma, http://www.lanthiopharma.com (2012, accessed 18 September 2012).
-
(2012)
-
-
-
17
-
-
8644281991
-
Design, synthesis, and biological evaluation of the first selective nonpeptide AT2 receptor agonist
-
Wan Y, Wallinder C, Plouffe B, et al. Design, synthesis, and biological evaluation of the first selective nonpeptide AT2 receptor agonist. J Med Chem. 2004 ; 47: 5995-6008
-
(2004)
J Med Chem
, vol.47
, pp. 5995-6008
-
-
Wan, Y.1
Wallinder, C.2
Plouffe, B.3
-
18
-
-
84871091482
-
-
Vicore Pharma accessed18 September 2012
-
Vicore Pharma, http://www.vicorepharma.com (2012, accessed18 September 2012).
-
(2012)
-
-
-
19
-
-
58149375072
-
Angiotensin II type 2 receptor stimulation: A novel option of therapeutic interference with the renin-angiotensin system in myocardial infarction?
-
Kaschina E, Grzesiak A, Li J, et al. Angiotensin II type 2 receptor stimulation: A novel option of therapeutic interference with the renin-angiotensin system in myocardial infarction?. Circulation. 2008 ; 118: 2523-2532
-
(2008)
Circulation
, vol.118
, pp. 2523-2532
-
-
Kaschina, E.1
Grzesiak, A.2
Li, J.3
-
20
-
-
84856479413
-
Direct stimulation of angiotensin II type 2 receptor enhances spatial memory
-
Jing F, Mogi M, Sakata A, et al. Direct stimulation of angiotensin II type 2 receptor enhances spatial memory. J Cereb Blood Flow Metab. 2012 ; 32: 248-255
-
(2012)
J Cereb Blood Flow Metab
, vol.32
, pp. 248-255
-
-
Jing, F.1
Mogi, M.2
Sakata, A.3
-
22
-
-
84871034291
-
-
Spinifex Pharmaceuticals accessed 18 September 2012
-
Spinifex Pharmaceuticals, http://www.spinifexpharma.com.au (2012, accessed 18 September 2012).
-
(2012)
-
-
-
23
-
-
35349001774
-
Study of angiotensin-(1-7) vasoactive peptide and its β-cyclodextrin inclusion complexes: Complete sequence-specific NMR assignments and structural studies
-
Lula I, Denadai AL, Resende JM, et al. Study of angiotensin-(1-7) vasoactive peptide and its β-cyclodextrin inclusion complexes: Complete sequence-specific NMR assignments and structural studies. Peptides. 2007 ; 28: 2199-2210
-
(2007)
Peptides
, vol.28
, pp. 2199-2210
-
-
Lula, I.1
Denadai, A.L.2
Resende, J.M.3
-
24
-
-
84871075227
-
-
Derma Sciences accessed 18 September 2012
-
Derma Sciences, http://www.dermasciences.com/ (2012, accessed 18 September 2012).
-
(2012)
-
-
-
25
-
-
84871061590
-
-
Tarix Pharmaceuticals accessed 18 September 2012
-
Tarix Pharmaceuticals, http://www.tarixpharma.com (2012, accessed 18 September 2012).
-
(2012)
-
-
-
26
-
-
84863475958
-
NorLeu3-A(1-7) stimulation of diabetic foot ulcer healing: Results of a randomized, parallel-group, double-blind, placebo-controlled phase 2 clinical trial
-
Balingit PP, Armstrong DG, Reyzelman AM, et al. NorLeu3-A(1-7) stimulation of diabetic foot ulcer healing: Results of a randomized, parallel-group, double-blind, placebo-controlled phase 2 clinical trial. Wound Repair Regen. 2012 ; 20: 482-490
-
(2012)
Wound Repair Regen
, vol.20
, pp. 482-490
-
-
Balingit, P.P.1
Armstrong, D.G.2
Reyzelman, A.M.3
-
27
-
-
58049193594
-
Discovery and validation of novel peptide agonists for G-protein-coupled receptors
-
Shemesh R, Toporik A, Levine Z, et al. Discovery and validation of novel peptide agonists for G-protein-coupled receptors. J Biol Chem. 2008 ; 283: 34643-34649
-
(2008)
J Biol Chem
, vol.283
, pp. 34643-34649
-
-
Shemesh, R.1
Toporik, A.2
Levine, Z.3
-
28
-
-
77953811506
-
Vascular relaxation, antihypertensive effect, and cardioprotection of a novel peptide agonist of the MAS receptor
-
Savergnini SQ, Beiman M, Lautner RQ, et al. Vascular relaxation, antihypertensive effect, and cardioprotection of a novel peptide agonist of the MAS receptor. Hypertension. 2010 ; 56: 112-120
-
(2010)
Hypertension
, vol.56
, pp. 112-120
-
-
Savergnini, S.Q.1
Beiman, M.2
Lautner, R.Q.3
-
29
-
-
84871039190
-
-
Compugen accessed 18 September 2012
-
Compugen, http://cgen.com (2007, accessed 18 September 2012).
-
(2007)
-
-
-
30
-
-
84871061282
-
-
accessed 18 September 2012
-
BioLineRx, http://www.biolinerx.com (2010, accessed 18 September 2012).
-
(2010)
BioLineRx
-
-
-
31
-
-
0036900194
-
AVE 0991, a nonpeptide mimic of the effects of angiotensin-(1-7) on the endothelium
-
Wiemer G, Dobrucki LW, Louka FR, et al. AVE 0991, a nonpeptide mimic of the effects of angiotensin-(1-7) on the endothelium. Hypertension. 2002 ; 40: 847-852
-
(2002)
Hypertension
, vol.40
, pp. 847-852
-
-
Wiemer, G.1
Dobrucki, L.W.2
Louka, F.R.3
-
32
-
-
84871044702
-
-
Apeiron Biologics accessed 18 September 2012
-
Apeiron Biologics, http://www.apeiron-biologics.com (2012, accessed 18 September 2012).
-
(2012)
-
-
-
33
-
-
42349105833
-
Structure-based identification of small-molecule angiotensin-converting enzyme 2 activators as novel antihypertensive agents
-
Prada JAH, Ferreira AJ, Katovich MJ, et al. Structure-based identification of small-molecule angiotensin-converting enzyme 2 activators as novel antihypertensive agents. Hypertension. 2008 ; 51: 1312-1317
-
(2008)
Hypertension
, vol.51
, pp. 1312-1317
-
-
Prada, J.A.H.1
Ferreira, A.J.2
Katovich, M.J.3
|